Clinical Trials on Meningococcal Meningitis, Serogroup W in Argentina

Total 5 results

Novartis Vaccines

Completed

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults

Meningococcal Infections | Meningococcal Meningitis

Argentina, Colombia
Novartis Vaccines
GlaxoSmithKline

Completed

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12

Meningococcal Disease | Meningococcal Meningitis

Belgium, Czechia, Germany, Italy, Spain, United Kingdom
Novartis Vaccines

Completed

Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants

Meningococcal Infections | Meningococcal Meningitis

Argentina, Chile, Czech Republic, Hungary, Italy
Novartis Vaccines

Completed

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

Meningitis, Meningococcal

United States, Argentina, Colombia
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

Meningitis, Meningococcal

United States, Australia, Argentina, Canada

3

Subscribe